FI952060A - Menetelmä atsitromysiinin annostamiseksi - Google Patents

Menetelmä atsitromysiinin annostamiseksi Download PDF

Info

Publication number
FI952060A
FI952060A FI952060A FI952060A FI952060A FI 952060 A FI952060 A FI 952060A FI 952060 A FI952060 A FI 952060A FI 952060 A FI952060 A FI 952060A FI 952060 A FI952060 A FI 952060A
Authority
FI
Finland
Prior art keywords
dosing
azithromycin
administering azithromycin
administering
disintrigrating
Prior art date
Application number
FI952060A
Other languages
English (en)
Swedish (sv)
Other versions
FI952060A0 (fi
Inventor
William J Curatolo
George H Foulds
Hylar L Friedman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22883977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI952060(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of FI952060A0 publication Critical patent/FI952060A0/fi
Publication of FI952060A publication Critical patent/FI952060A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
FI952060A 1994-04-29 1995-04-28 Menetelmä atsitromysiinin annostamiseksi FI952060A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/235,069 US5605889A (en) 1994-04-29 1994-04-29 Method of administering azithromycin

Publications (2)

Publication Number Publication Date
FI952060A0 FI952060A0 (fi) 1995-04-28
FI952060A true FI952060A (fi) 1995-10-30

Family

ID=22883977

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952060A FI952060A (fi) 1994-04-29 1995-04-28 Menetelmä atsitromysiinin annostamiseksi

Country Status (31)

Country Link
US (2) US5605889A (fi)
EP (1) EP0679400B1 (fi)
JP (3) JPH07300420A (fi)
KR (1) KR100354310B1 (fi)
CN (1) CN1088362C (fi)
AP (1) AP566A (fi)
AT (1) ATE183395T1 (fi)
AU (1) AU709328B2 (fi)
CA (1) CA2148071C (fi)
CO (1) CO4560547A1 (fi)
DE (1) DE69511451T2 (fi)
DK (1) DK0679400T3 (fi)
DZ (1) DZ1877A1 (fi)
ES (1) ES2136247T3 (fi)
FI (1) FI952060A (fi)
GR (1) GR3031290T3 (fi)
HU (1) HUT75244A (fi)
IL (1) IL113437A (fi)
LV (1) LV10918B (fi)
MA (1) MA23533A1 (fi)
NO (1) NO314386B1 (fi)
NZ (1) NZ548384A (fi)
OA (1) OA10151A (fi)
RU (1) RU2128998C1 (fi)
SI (1) SI0679400T1 (fi)
TN (1) TNSN95046A1 (fi)
TW (1) TW499311B (fi)
UA (1) UA34464C2 (fi)
UY (1) UY23935A1 (fi)
YU (1) YU49483B (fi)
ZA (1) ZA953439B (fi)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2977907B2 (ja) * 1994-05-06 1999-11-15 ファイザー・インコーポレーテッド アジスロマイシンの放出調節された剤形
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
EA003736B1 (ru) * 1995-02-08 2003-08-28 Яманучи Юроп Б.В. Лекарственная форма для перорального введения, содержащая бета-лактамный антибиотик
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6146655A (en) * 1997-08-29 2000-11-14 Softy-Flex Inc. Flexible intra-oral bandage and drug delivery system
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US6861411B1 (en) * 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
PE20000066A1 (es) * 1997-12-22 2000-02-09 Schering Corp Formas de dosificacion solida de ribavirina administrables oralmente y proceso de fabricacion
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
CA2371940C (en) * 1999-03-31 2008-07-15 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
DE60026718T2 (de) * 2000-07-25 2006-11-16 Laboratorio Silanes, S.A. De C.V. Einstufiges verfahren zur herstellung von 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle(11.2.11)hexadeca-1(2)-en-8-ona undeine neue form von 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a
ATE306491T1 (de) 2000-08-23 2005-10-15 Wockhardt Ltd Verfahren zur herstellung von wasserfreiem azithromycin
EP2295533A3 (en) * 2000-11-06 2011-07-13 Life Technologies Corporation Dry powder cells and cell culture reagents and methods of production thereof
JP3836790B2 (ja) * 2000-11-15 2006-10-25 昌雄 菅又 子宮内膜症の予防又は治療薬
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1671979B1 (en) 2001-05-22 2008-08-13 Pfizer Products Inc. New Cristal Form of Azithromycin
EA007618B1 (ru) * 2001-05-22 2006-12-29 Пфайзер Продактс Инк. Кристаллический полуторогидрат азитромицина, содержащая его фармацевтическая композиция и способ лечения на его основе
SK1012004A3 (sk) * 2001-08-21 2005-04-01 Pfizer Products Inc. Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
DE60232005D1 (de) * 2001-10-18 2009-05-28 Teva Pharma Stabilisierte azithromycin-zusammensetzungen
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
NZ532707A (en) * 2001-12-21 2006-07-28 Pfizer Prod Inc Directly compressible formulations of azithromycin
BR0215175A (pt) * 2001-12-21 2004-12-28 Pfizer Prod Inc Métodos para a granulação úmida de azitromicina
WO2003061728A2 (en) * 2002-01-16 2003-07-31 Pepgen Corporation Oral administration of interferon-tau
JP2005526020A (ja) * 2002-02-01 2005-09-02 ファイザー・プロダクツ・インク アジスロマイシンの乾式造粒配合物
EP1490031A1 (en) * 2002-03-07 2004-12-29 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BG748Y1 (bg) * 2002-07-02 2005-06-30 "BALKANFARMA-RAZGRAD" AD A{ô­{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@
EP1594762A1 (en) * 2003-02-19 2005-11-16 Teva Pharmaceutical Industries Limited Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container
JP2006528689A (ja) * 2003-05-06 2006-12-21 ムルイェ、ニルマル エリスロマイシン誘導体の徐放製剤
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US7572773B2 (en) * 2003-07-24 2009-08-11 Pliva Hrvatska D.O.O. Single dose fast dissolving azithromycin
AR045142A1 (es) 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
WO2005053653A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
UA78793C2 (en) * 2003-12-04 2007-04-25 Pfizer Prod Inc Oral dosage form of azitromycin with decreased side effects
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
RU2006119453A (ru) * 2003-12-04 2007-12-20 Пфайзер Продактс Инк. (Us) Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц
EP1691787B1 (en) * 2003-12-04 2008-07-02 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co IMPROVING THE IMMUNE RESPONSE
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
EP1843761B1 (en) * 2005-01-27 2018-01-31 Alembic Limited Extended release formulation of levetiracetam
ATE437644T1 (de) * 2005-03-07 2009-08-15 Teva Pharma Azithromycin-puolver für orale suspensionszusammensetzungen
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
CN102048734B (zh) 2005-05-26 2013-11-20 大日本住友制药株式会社 药物组合物
CA2618977C (en) * 2005-08-10 2014-10-21 Shionogi & Co., Ltd. Orally disintegratable tablet
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
JP5849947B2 (ja) 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
US9233100B2 (en) 2012-02-06 2016-01-12 Merial, Inc. Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
EP2821066B1 (en) 2012-02-28 2018-04-25 Seoul Pharma. Co. Ltd. High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
EP3068227A4 (en) * 2013-11-11 2017-06-21 Forest Laboratories Holdings Limited Compositions and methods of treatment comprising fosfomycin disodium
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4382085A (en) * 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
UA27040C2 (uk) 1987-07-09 2000-02-28 Пфайзер Інк. Кристалічhий дигідрат азитроміциhу та спосіб одержаhhя кристалічhого дигідрату азитроміциhу
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
WO1992006991A1 (fr) * 1990-10-15 1992-04-30 Taisho Pharmaceutical Co., Ltd. Erythromycine modifiee en 2' ou derive de cette substance
TW271400B (fi) 1992-07-30 1996-03-01 Pfizer
EP0721324A1 (en) 1993-10-01 1996-07-17 The Procter & Gamble Company Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
JP2977907B2 (ja) 1994-05-06 1999-11-15 ファイザー・インコーポレーテッド アジスロマイシンの放出調節された剤形

Also Published As

Publication number Publication date
LV10918B (en) 1996-06-20
NO951630D0 (no) 1995-04-28
KR100354310B1 (ko) 2002-12-26
IL113437A (en) 2001-04-30
YU49483B (sh) 2006-08-17
FI952060A0 (fi) 1995-04-28
CO4560547A1 (es) 1998-02-10
NO314386B1 (no) 2003-03-17
HU9501206D0 (en) 1995-06-28
GR3031290T3 (en) 1999-12-31
OA10151A (en) 1996-12-18
KR950028764A (ko) 1995-11-22
SI0679400T1 (en) 1999-10-31
US5605889A (en) 1997-02-25
DE69511451D1 (de) 1999-09-23
ATE183395T1 (de) 1999-09-15
TNSN95046A1 (fr) 1996-02-06
EP0679400A1 (en) 1995-11-02
CN1088362C (zh) 2002-07-31
TW499311B (en) 2002-08-21
IL113437A0 (en) 1995-07-31
JPH07300420A (ja) 1995-11-14
EP0679400B1 (en) 1999-08-18
RU2128998C1 (ru) 1999-04-20
ES2136247T3 (es) 1999-11-16
MA23533A1 (fr) 1995-12-31
DZ1877A1 (fr) 2002-02-17
UY23935A1 (es) 1995-09-12
AP566A (en) 1996-11-22
USRE39149E1 (en) 2006-06-27
UA34464C2 (uk) 2001-03-15
JP2005015466A (ja) 2005-01-20
NO951630L (no) 1995-10-30
CA2148071C (en) 2000-10-17
YU27195A (sh) 1999-03-04
DE69511451T2 (de) 1999-12-09
CA2148071A1 (en) 1995-10-30
NZ548384A (en) 2008-04-30
RU95106639A (ru) 1997-01-20
AU709328B2 (en) 1999-08-26
CN1114879A (zh) 1996-01-17
AU1771195A (en) 1995-11-09
JP2008231120A (ja) 2008-10-02
LV10918A (lv) 1995-12-20
HUT75244A (en) 1997-05-28
ZA953439B (en) 1996-10-28
AP9500728A0 (en) 1995-04-30
DK0679400T3 (da) 1999-12-06

Similar Documents

Publication Publication Date Title
FI952060A (fi) Menetelmä atsitromysiinin annostamiseksi
DK0430474T3 (da) Præparater med vedvarende frigivelse til behandling af periodontal sygdom
ATE151282T1 (de) Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung periodontaler erkrankungen
DK20488D0 (da) Farmaceutiske praeparater med forlaenget afgivelse
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
DE3775805D1 (de) Arzneimittel zur behandlung periodontaler erkrankungen.
GR3018933T3 (en) Use of monoolein in the treatment of the periodontal pocket
DE69025271D1 (de) Pharmazeutische Zubereitungen mit verzögerter Freisetzung zur Behandlung periodontaler Erkrankungen
NO862611L (no) Tann- og munnbehandlingspreparat.
ATE281159T1 (de) Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
EP0313654A4 (en) MEDICINAL PRODUCTS FOR PROPHYLAXIS AND TREATMENT OF LIVER DISEASES.
DE3851971D1 (de) Verwendung antigener Substanzen zur Prophylaxe oder Therapie von Störungen und Krankheiten im Verdauungstrakt von Tieren und Menschen.
GR3007995T3 (fi)
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
PH24723A (en) Device and composition for treatment of the gums
ITRM990339A0 (it) Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali deriva
DK99993D0 (da) Treatment and prophylaxis of diseases caused by parasites or bacteria
KR900009029A (ko) 가축병 치료용 약물을 투여하는 장치
FR2691360B1 (fr) Compositions pharmaceutiques destinees en particulier au traitement des poches parondontales et procede de fabrication.
ATE92763T1 (de) Mittel zur behandlung des parkinson-syndroms.
RU97115532A (ru) Способ лечения воспалительных заболеваний пародонта
TH6324EX (th) อุปกรณ์สำหรับใช้ในการรักษาโรคเหงือก
DK31292D0 (da) Treatment and prophylaxis of diseases caused by parasites or bacteria
ATE59776T1 (de) Pharmazeutische zusammensetzung und behandlung.

Legal Events

Date Code Title Description
FD Application lapsed